Qingshu Meng

Research Assistant Professor

Northwestern University Feinberg School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Year:

2026

Year:

2025

EGFR amplification frequently happens within extrachromosome DNAs (ecDNAs) and is a major mutation in glioblastoma (GBM). However, targeting EGFR for GBM treatments has been unsuccessful. Here we characterized a long non-coding RNA (lncRNA) that is co-amplified with EGFR within ecDNAs that we name hidden EGFR long non-coding downstream RNA (HELDR). HELDR is a GBM-specific lncRNA that promotes tumorigenicity independent of EGFR signaling. HELDR globally binds genomic DNA and recruits the transcription co-activator p300 to the KAT7 promoter. p300-induced H3K27ac at the KAT7 promoter enlists other co-transcription factors, activating KAT7 transcription. KAT7 induces H3K14ac and H4K12ac that activate KAT7-driven gene programs that are critical for GBM malignancy. Targeting KAT7 or HELDR markedly enhances therapeutic effects of anti-EGFR treatments for GBM. These results not only reveal the role of HELDR in EGFR-driven GBM but also provide a strong rationale to characterize the role of lncRNAs co-amplified with driver oncogenes in human cancers.

Year:

2025

DNA repair dysregulation is a key driver of cancer development. Understanding the molecular mechanisms underlying DNA repair dysregulation in cancer cells is crucial for cancer development and therapies. Here, we report that enhancer of zeste homolog 2 (EZH2) directly methylates poly(adenosine diphosphate–ribose) polymerase-1 (PARP-1), an essential enzyme involved in DNA repair, and regulates its activity. Functionally, EZH2-catalyzed methylation represses PARP1 catalytic activity, down-regulates the recruitment of x-ray repair cross-complementing group-1 to DNA lesions and its associated DNA damage repair; on the other hand, it protects the cells from nicotinamide adenine dinucleotide overconsumption upon DNA damage formation. Meanwhile, EZH2-mediated methylation regulates PARP1 transcriptional and oncogenic activity, at least in part, through impairing PARP1-E2F1 interaction and E2F1 transcription factor activity. EZH2 and PARP1 inhibitors synergistically suppress prostate cancer growth. Collectively, our findings uncover an insight of EZH2 functions in fine-tuning PARP1 activity during DNA damage repair and cancer progression, which provides a rationale for combinational targeting EZH2 and PARP1 in cancer.

Year:

2024

Year:

2023

Year:

2023

Collaborators (13)

Rendong Yang

Associate Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Xiaoyu Zhang

Assistant Professor

Northwestern University

UNITED STATES
View details

Xuesen Dong

Professor

The University of British Columbia

CANADA
View details

Shiyuan Cheng

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Dongyu Zhao

Assistant Professor

Peking University

CHINA
View details

Song Xiao

Assistant Professor

Medical University of South Carolina

UNITED STATES
View details

Luke Hoeppner

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Douglas Yee

Professor

University of Minnesota

UNITED STATES
View details

TINGYOU WANG

Research Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Sk. Kayum Alam

Researchers, Research Professional 5

University of Minnesota

UNITED STATES
View details

Qi Cao

Associate Professor

Northwestern University

UNITED STATES
View details

Longhou Fang

Associate Professor

Houston Methodist Research Institute

UNITED STATES
View details